HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.

Abstract
Glucuronidation by uridine 5-diphosphoglucuronosyl transferase enzymes (UGTs) is a cause of intrinsic drug resistance in cancer cells. Glucuronidation of combretastatin A-4 (CA-4) was previously identified as a mechanism of resistance in hepatocellular cancer cells. Herein, we propose chemical manipulation of β-lactam bridged analogues of Combretastatin A-4 as a novel means of overcoming drug resistance associated with glucuronidation due to the expression of UGTs in the CA-4 resistant human colon cancer HT-29 cells. The alkene bridge of CA-4 is replaced with a β-lactam ring to circumvent potential isomerisation while the potential sites of glucuronate conjugation are deleted in the novel 3-substituted-1,4-diaryl-2-azetidinone analogues of CA-4. We hypothesise that glucuronidation of CA-4 is the mechanism of drug resistance in HT-29 cells. Ring B thioether containing 2-azetidinone analogues of CA-4 such as 4-(4-(methylthio)phenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (27) and 3-hydroxy-4-(4-(methylthio)phenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (45) were identified as the most potent inhibitors of tumour cell growth, independent of UGT status, displaying antiproliferative activity in the low nanomolar range. These compounds also disrupted the microtubular structure in MCF-7 and HT-29 cells, and caused G2/M arrest and apoptosis. Taken together, these findings highlight the potential of chemical manipulation as a means of overcoming glucuronidation attributed drug resistance in CA-4 resistant human colon cancer HT-29 cells, allowing the development of therapeutically superior analogues.
AuthorsAzizah M Malebari, Lisa M Greene, Seema M Nathwani, Darren Fayne, Niamh M O'Boyle, Shu Wang, Brendan Twamley, Daniela M Zisterer, Mary J Meegan
JournalEuropean journal of medicinal chemistry (Eur J Med Chem) Vol. 130 Pg. 261-285 (Apr 21 2017) ISSN: 1768-3254 [Electronic] France
PMID28254699 (Publication Type: Journal Article)
CopyrightCopyright © 2017 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Glucuronates
  • Stilbenes
  • beta-Lactams
  • fosbretabulin
Topics
  • Antineoplastic Agents, Phytogenic
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Colonic Neoplasms (pathology)
  • Drug Resistance, Neoplasm
  • Glucuronates (metabolism)
  • HT29 Cells
  • Humans
  • Inactivation, Metabolic
  • Stilbenes (chemistry, metabolism, pharmacokinetics)
  • Structure-Activity Relationship
  • beta-Lactams (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: